Triapine

Generic Name: Triapine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₇H_₉N_₅S

CAS Number: 143621-35-6

Unique Ingredient Identifier: U4XIL4091C

Background: Triapine has been used in trials studying the treatment of Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2

Recruiting

Conditions: Metastatic Neuroendocrine Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lutetium Lu 177 Dotatate
Procedure: Magnetic Resonance Imaging
Drug: Triapine

First Posted Date: 2023-02-13

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT05724108

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 23 locations

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Early Phase 1

Suspended

Conditions: Endometrial Serous Adenocarcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Resection
Drug: Triapine

First Posted Date: 2020-07-31

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT04494113

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 4 locations

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Digestive System Neuroendocrine Neoplasm
Metastatic Neuroendocrine Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lutetium Lu 177 Dotatate
Procedure: Magnetic Resonance Imaging
Drug: Triapine

First Posted Date: 2020-01-21

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT04234568

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 8 locations

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Phase 1

Active, not recruiting

Conditions: Stage II Vaginal Cancer AJCC v6 and v7
Stage IVA Vaginal Cancer AJCC v6 and v7
Advanced Vaginal Adenocarcinoma
Advanced Vaginal Adenosquamous Carcinoma
Advanced Vaginal Squamous Cell Carcinoma
Stage IVA Cervical Cancer AJCC v6 and v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Advanced Cervical Adenocarcinoma
Advanced Cervical Adenosquamous Carcinoma
Advanced Cervical Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Radiation: Brachytherapy
Drug: Cisplatin
Procedure: Computed Tomography
Radiation: External Beam Radiation Therapy
Other: Fludeoxyglucose F-18
Radiation: High-Dose Rate Brachytherapy
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Procedure: Positron Emission Tomography
Drug: Triapine

First Posted Date: 2015-11-04

Last Posted Date: 2024-11-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT02595879

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 14 locations

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3

Active, not recruiting

Conditions: Advanced Vaginal Adenocarcinoma
Stage II Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage IVA Vaginal Cancer AJCC v6 and v7
Unresectable Vaginal Carcinoma
Vaginal Adenocarcinoma
Cervical Adenocarcinoma
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma

Interventions: Radiation: Brachytherapy
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy
Drug: Triapine

First Posted Date: 2015-06-09

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 450

Registration Number: NCT02466971

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Memorial Hermann Texas Medical Center, Houston, Texas, United States
🇺🇸
Methodist Willowbrook Hospital, Houston, Texas, United States

and more 380 locations

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Phase 2

Completed

Conditions: Recurrent Cervical Cancer
Recurrent Vaginal Cancer
Stage IVA Vaginal Cancer
Stage IVB Cervical Cancer
Therapy-related Toxicity
Stage II Vaginal Cancer
Stage IIB Cervical Cancer
Stage IVA Cervical Cancer
Stage IVB Vaginal Cancer
Stage III Cervical Cancer

Interventions: Drug: triapine
Drug: cisplatin
Radiation: external beam radiation therapy
Procedure: quality-of-life assessment
Other: questionnaire administration
Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography
Procedure: computed tomography

First Posted Date: 2009-07-17

Last Posted Date: 2017-11-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00941070

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

3-AP in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: triapine
Other: pharmacological study
Procedure: laboratory biomarker analysis

First Posted Date: 2006-10-19

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00390052

Locations: 🇺🇸
City of Hope, Duarte, California, United States

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Eosinophilic Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelomonocytic Leukemia
Essential Thrombocythemia
Philadelphia Chromosome Negative Chronic Myelogenous Leukemia
Polycythemia Vera
Primary Myelofibrosis
Accelerated Phase Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia

Interventions: Drug: fludarabine phosphate
Drug: triapine
Procedure: laboratory biomarker analysis

First Posted Date: 2006-09-28

Last Posted Date: 2015-01-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00381550

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Phase 1

Completed

Conditions: Recurrent Cervical Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Vaginal Cancer
Recurrent Vulvar Cancer
Stage III Vaginal Cancer
Stage IIIA Cervical Cancer
Stage IIIA Ovarian Epithelial Cancer
Stage IIIB Ovarian Epithelial Cancer
Stage IIIB Vulvar Cancer
Stage IIIC Ovarian Epithelial Cancer

Interventions: Drug: triapine
Other: laboratory biomarker analysis
Radiation: external beam radiation therapy
Radiation: brachytherapy
Drug: cisplatin
Other: pharmacological study

First Posted Date: 2006-06-12

Last Posted Date: 2013-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00335998

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Primary Central Nervous System Hodgkin Lymphoma
Primary Central Nervous System Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: gemcitabine hydrochloride
Drug: triapine

First Posted Date: 2006-02-17

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00293345

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy